Terns Pharmaceuticals
$52.95
43
+$0.02+0.04% Monday 20:00
Statistics
Day High
52.98
Day Low
52.95
52W High
53.17
52W Low
2.78
Volume
6,331,482
Avg. Volume
-
Mkt Cap
4.77B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
18MayExpected
Expected EPS
-0.251667
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-177.71MNet Income
Analyst Ratings
52.5Average Price Target
The highest estimate is 56.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy 44%
Hold 56%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow TERN. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap163.4B
Madrigal Pharmaceuticals
MDGL
Mkt Cap11.84B
Viking Therapeutics
VKTX
Mkt Cap3.48B
Galmed Pharmaceuticals
GLMD
Mkt Cap3.77M
Agios Pharmaceuticals
AGIO
Mkt Cap1.67B
Enanta Pharmaceuticals
ENTA
Mkt Cap421.94M
About
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Show more...
CEO
Ms. Amy L. Burroughs M.B.A.
Employees
59
Country
United States
ISIN
US8808811074
Listings
0 Comments
Share your thoughts
FAQ
What is Terns Pharmaceuticals stock price today?▼
The current price of TERN is $52.95 USD — it has increased by +0.04% in the past 24 hours. Watch Terns Pharmaceuticals stock price performance more closely on the chart.
What is Terns Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Terns Pharmaceuticals stocks are traded under the ticker TERN.
Is Terns Pharmaceuticals stock price growing?▼
TERN stock has risen by +0.06% compared to the previous week, the month change is a +0.32% rise, over the last year Terns Pharmaceuticals has showed a +1,659.14% increase.
What is Terns Pharmaceuticals market cap?▼
Today Terns Pharmaceuticals has the market capitalization of 4.77B
When is the next Terns Pharmaceuticals earnings date?▼
Terns Pharmaceuticals is going to release the next earnings report on May 18, 2026.
What were Terns Pharmaceuticals earnings last quarter?▼
TERN earnings for the last quarter are -0.27 USD per share, whereas the estimation was -0.29 USD resulting in a +6.18% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Terns Pharmaceuticals revenue for the last year?▼
Terns Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Terns Pharmaceuticals net income for the last year?▼
TERN net income for the last year is -177.71M USD.
How many employees does Terns Pharmaceuticals have?▼
As of May 06, 2026, the company has 59 employees.
In which sector is Terns Pharmaceuticals located?▼
Terns Pharmaceuticals operates in the Health & Wellness sector.
When did Terns Pharmaceuticals complete a stock split?▼
The last stock split for Terns Pharmaceuticals was on May 08, 2000 with a ratio of 2:1.
Where is Terns Pharmaceuticals headquartered?▼
Terns Pharmaceuticals is headquartered in Foster City, United States.